Alm. Brand A/S
Alm. Brand A/S - Completion of proportionate buyback of shares from Foreningen Alm. Brand af 1792 fmba
Alm. Brand A/S - Completion of proportionate buyback of shares from Foreningen Alm. Brand af 1792 fmba
Today, Alm. Brand Group A/S has completed a block buyback of 47,710,542 shares for a total amount of DKK 764,8 million from Foreningen Alm. Brand af 1792 fmba, equivalent to 47.8% of the total share buyback of DKK 1.6 billion announced on 22 January 2025 through company announcement no. 4/2025. The buyback is related to the divestement of Energy & Marine. The block buyback was completed to maintain Foreningen Alm. Brand af 1792 fmba’s percentage ownership interest in Alm. Brand Group A/S following completion of the total share buyback. The block buyback was completed at the closing price of the company’s shares on Nasdaq Copenhagen on 4 March 2025.
In accordance with section 31 of the Danish Capital Markets Act, Alm. Brand A/S hereby announces that the portfolio of treasury shares now exceeds 5% of the shares in Alm. Brand A/S.
Contact
Please direct any questions regarding this announcement to:
Head of IR, Rating and ESG reporting
Mads Thinggaard
Mobile no. +45 2025 5469
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Constellation Brands, Inc.7.1.2026 22:05:00 CET | Press release
Constellation Brands Reports Third Quarter Fiscal 2026 Financial Results
Oil-Dri Corporation Of America7.1.2026 22:00:00 CET | Press release
Amlan International Brings Gut Health and Feed Efficiency Innovation to IPPE 2026
DBV Technologies S.A.7.1.2026 22:00:00 CET | Press release
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
King Faisal Prize7.1.2026 19:01:34 CET | Press release
Pioneering Scientist Behind Revolutionary Weight-Loss Drugs and Leading Mathematician Honored with 2026 King Faisal Prize
Herantis Pharma plc7.1.2026 19:01:06 CET | Press release
Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom